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Abstract Aging is accompanied by reduced regen-
erative capacity of all tissues and organs and dysfunc-
tion of adult stem cells. Notably, these age-related
alterations contribute to distinct pathophysiological
characteristics depending on the tissue of origin and
function and thus require special attention in a type by
type manner. In this paper, we review the current
understanding of the mechanisms leading to tissue-
specific adult stem cell dysfunction and reduced
regenerative capacity with age. A comprehensive
investigation of the hematopoietic, the neural, the
mesenchymal, and the skeletal stem cells in age-
related research highlights that distinct mechanisms
are associated with the different types of tissue stem
cells. The link between age-related stem cell dysfunc-
tion and human pathologies is discussed along with the
challenges and the future perspectives in stem cell-
based therapies in age-related diseases.
Keywords Adult stem cells  Aging 
Regeneration  Age-related diseases  Stem cell
therapy
Introduction
Adult stem cells, or resident stem cells, are undiffer-
entiated cells found in adults throughout life (Passier
and Mummery 2003). These cells are characterized by
two developmental capacities: self-renewal, the ability
to give rise to daughter stem cells, and multipotency,
the capacity to differentiate into various cell types of a
particular organ. These properties provide stem cells
the ability to sustain their population during life, and to
maintain tissue remodeling and repair (Bryder et al.
2006), facilitating the rationale for using adult stem
cells in regenerative medicine (Mimeault et al. 2007).
Nevertheless, it is still under continuous debate: which
type of stem cells is most suitable for regenerative
therapy; the embryonic stem cells, the induced
pluripotent stem cells (iPSCs), or the adult stem cells
(Abramovich et al. 2008; Passier and Mummery 2003;
Robinton and Daley 2012; Symonds et al. 2009;
Yamanaka 2009).
Stem cell function declines with age and this occurs
at multiple levels, including self-renewal and differ-
entiation potential, leading to reduced regenerative
capacity of all tissues and organs. Moreover, age-
related alterations in stem cells contribute to distinct
pathophysiological characteristics depending on the
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tissue of origin and function. Thus, given the perspec-
tives of adult stem cells in regenerative therapy,
understanding these processes and their role in age-
related diseases (ARDs) is vital.
Here, we present a comprehensive overview of
recent achievements and debates about the dysregu-
lation of four types of tissue stem cells in the elderly
(hematopoietic, neural, mesenchymal, and skeletal
stem cells), highlighting that distinct age-related
effects are associated with the different types of tissue
stem cells. We analyze how the dysfunction of the
tissue stem cells and the decrease in regeneration
potential are associated with age and ARDs (Table 1).
Last but not least, we explore recent progress and
challenges of stem cell-based therapies in light of
current progress in the field of aging. The cellular
hallmarks of aging and the intrinsic pathways leading
to stem cell dysfunction with age are fundamental and
relevant issues, but are beyond the scope of this paper
and reviewed elsewhere (Moskalev et al. 2012; Lopez-
Otin et al. 2013; Tacutu et al. 2011).
Hematopoietic stem cells
Hematopoietic stem cells (HSCs), first identified in the
1960s (Becker et al. 1963; Till and Mc 1961), are
morphologically small cells, with high nucleus to
cytoplasm ratio and are defined immunophenotypi-
cally by a distinct surface marker expression profile.
Human HSCs do not express the markers of differen-
tiated blood lineages (lin minus cells) but are charac-
terized by CD34/CD90 positivity and CD38/CD45RA
negativity. Recently, the identification of the integrin
molecule CD45f provided a means to isolate the long-
term engrafting multipotent HSC population. Based
on these markers, the number and the frequency of
HSCs were easily measured, and cells were purified
for further analysis from different age groups (Notta
et al. 2011).
Age-related changes in HSCs
In terms of the age-related alterations, HSCs are the
most understood cells when compared to other types
of tissue stem cells. With age, an overall functional
decline in the hematopoietic system is characterized
by reduced lymphoid cell and increased myeloid cell
population with attenuated immune functions. Thus,
age-related changes in the blood system are at least
partially attributed to HSCs that reside in the bone
marrow microenvironment and are responsible for the
continuous blood cell supply (Woolthuis et al. 2011).
HSC pool and differentiation potential
With age, the bone marrow undergoes structural
changes, such as the reduced proportion of active
blood-forming bone marrow and the decreased overall
cellularity. At a young age, the hematopoiesis takes
place in the cavities of long bones, however, during
adulthood it becomes restricted to certain bones,
including the sternum, the vertebrae and the pelvis
(Pearce et al. 2007). According to a long-standing
paradigm, the mechanism underlying this phenome-
non is the reduced HSC pool in aged individuals.
However, based on more accurate stem cell purifica-
tion methods, it has been recently shown that in
humans the HSC population rather increases with age
(Kuranda et al. 2011; Pang et al. 2011). The well-
studied (C57BL/6) mouse HSC system provided an
elegant model to resolve the ‘‘decreased blood cell
function versus increased HSC pool’’ discrepancy
(Muller-Sieburg et al. 2012). It was concluded that the
HSC population is heterogeneous and different stem
cells sub-populations with distinct differentiation
capacities coexist in the bone marrow. HSCs were,
therefore, classified into three subsets depending on
their differentiation capacities to produce either lym-
phoid cells (lymphoid-biased), myeloid cells (mye-
loid-biased), or both (balanced). As HSCs age, the
myeloid-biased HSCs accumulate at the expense of
the lymphoid-biased HSC subset (Muller-Sieburg
et al. 2012). This compositional shift towards the
enlarged myeloid-biased HSCs may explain the age-
associated increase in HSC population with myeloid
skewing and the lymphoid lineage deficiency in the
elderly (Cho et al. 2008). Moreover, the CD150
marker expression can be used to distinguish between
the subsets of murine HSCs (Beerman et al. 2010):
myeloid-biased cells and balanced HSCs express
CD150 at high or lower level, respectively. Further-
more, differentiation and self-renewal programs are
epigenetically stable in each HSC subset. This means
that pre-programmed differentiation fate is stably
inherited within the HSC clone. For example, a
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myeloid-biased HSC will give rise to myeloid-biased
daughter stem cells throughout the life of the organ-
ism. Notably, the lifespan of a clone determines the
representation of the particular HSC subset. Therefore,
in this case, the myeloid-biased HSCs may have a
higher self-renewal capacity than the lymphoid coun-
terpart, leading to myeloid dominance at an advanced
age (Muller-Sieburg et al. 2004). It should be noted
that HSCs have a broad differentiation capacity and
these cells can give rise not only to myeloid and
lymphoid cell lineages but also to several other tissue
cell types (Ogawa et al. 2013). However, to the best of
our knowledge, there is currently no information on
how the age related alterations affect the pluripotent
nature of HSCs.
HSCs and their microenvironment
Along with the age-associated hematopoietic cell-
intrinsic changes, including lineage potential and
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HSCs lifespan, it should be emphasized that HSCs
have a special home in the bone marrow (the HSC
niche) and the interactions between the HSCs and their
microenvironment are also altered with age (Van Zant
and Liang 2012).
HSCs are located in intimate contact with their
surrounding niche/stromal cells, localized mainly
around the sinusoidal/endothelial cells and in the
endosteal region of the bone marrow (Shen and
Nilsson 2012). Importantly, HSCs receive several
surviving stimuli from their niche cells. This is
supported by the long standing observation that HSCs
rapidly loose stem cell properties ex vivo, i.e., without
their physiological microenvironment. What are the
extrinsic niche-derived signals that influence the aging
process in the hematopoietic system? The full picture
is not clear yet. The accumulating evidence indicate
that the age-related changes in HSC microenviron-
ment and the niche signals, along with the intrinsically
regulated differentiation processes, have a strong
impact on HSC properties (Wagner et al. 2008).
Age-associated alterations in the bone marrow
composition include the general loss of bone mass
due to decreased bone formation, accumulation of
fat cells, altered extracellular matrix elements and
reduced transforming growth factor (TGF)-beta
levels (Bellantuono et al. 2009). It is not clear yet
and remains to be established how the aged niche
influences the stem cell population. In elderly
people, HSCs have a reduced ability to home the
niche upon bone marrow transplantation and in
elderly people the HSC can be mobilized more
easily after granulocyte-colony stimulating factor
(G-CSF) administration than in young individuals
(Geiger et al. 2007). HSC’s homing and mobilization
processes depend on cell adhesion molecules. There-
fore, it is not surprising that integrins (a4, a5) and
the cell adhesion molecule, VCAM-1, are expressed
at higher levels in young than in old HSCs,
supporting the notions that the aged HSCs adhere
less efficiently to the aged stromal cells and that the
cross-talk between HSCs and the microenvironment
is compromised (Xing et al. 2006). Interestingly,
in vivo the old progenitor cells are located more
distant from the endosteal niche cells in the bone
marrow than young cells, suggesting that the altered
niche-HSC synapses play a role in the observed age-
related changes in the stem cell homing and the
mobilization (Kohler et al. 2009).
HSCs as pathophysiological determinants in aging
Age-related changes in HSCs may be responsible for
multiple pathological conditions in the elderly popula-
tion (Rothstein 2003; Signer et al. 2007). The decline of
the lymphoid cell production leads to impaired immune
defense and higher susceptibility to infections. The
consequence of the smaller lymphocyte population is
the reduced number of B and T cell clones, leading to
the production of less diverse antibody and T-cell
receptor repertoires with age. Under these conditions,
the probability to acquire autoimmune diseases greatly
increases. Along with these effects, the enlarged but
functionally impaired myeloid cell population creates a
pro-inflammatory milieu in the body. As the immune
cells are not localized in one defined area in the body,
the age-related pro-inflammatory environment and the
compromised immunosurveillance also favor the emer-
gence of non-hematopoietic cancers (von Figura and
Rudolph 2009). The most detrimental aspect of aging in
the hematopoietic system is however the exponential
increase of leukemias with age (Dombret et al. 2008;
Vas et al. 2012). Moreover, whereas childhood malig-
nancies predominantly involve lymphoid leukemia, the
leukemias in the elderly have mainly myeloid origin,
reflecting the age-associated myeloid skewing of the
HSC population (Henry et al. 2011; Rossi et al. 2008).
In addition to the age-associated hematopoietic
disorders mentioned above, anemic status with low
erythrocyte count in the blood is very common in
elderly. One of the difficulties in studying age-related
anemia is that in many cases, the de facto cause of
inefficient red blood cell production is unclear and,
therefore, they are referred as ‘‘unexplained anemia in
the elderly’’ (UAE) (Merchant and Roy 2012). One
possible explanation is that the levels of erythropoi-
etin, a survival factor of the erythroid precursors, is
relatively low in UAE patients and consequently the
red blood cell production is reduced.
Future perspectives
The two main consequences of HSC aging—the
decline in their functional capacities and imbalance
in blood cell production—may greatly contribute to
organismal aging and the development of age-related
pathology. Some of the age-associated effects, such as
the accumulation of genomic insults and telomere
shortening, are generally considered irreversible,
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whereas other effects, such as epigenetic modifica-
tions and signaling pathway switches, are potentially
reversible (Mendelsohn and Larrick 2013; Pollina and
Brunet 2011).
With this in mind, valuable efforts have been
undertaken to rejuvenate old HSCs. For example, a
recently discovered Cdc42 inhibitor molecule
(CASIN) was able to functionally rejuvenate old
murine HSCs. Cdc42 is a small RhoGTP-ase that by
regulating the cytoskeletal organization is involved in
several signalling pathways and epigenetic processes,
including genome markings by histones (Lugert et al.
2010). Following CASIN treatment, the lymphoid cell
production of old HSCs increased and the epigenetic
status (measured by H4K16Ac level) of the old HSCs
was restored (Florian et al. 2012). Along the same line
of evidence, restoring the activity of a mammalian
sirtuin SIRT3, shown to be reduced in aged murine
HSCs, rejuvenated these cells as demonstrated by
in vitro colony forming assay and in vivo transplan-
tation experiments (Brown et al. 2013). SIRT3
reduced oxidative stress, known to alter histone
deacetylase (HDAC) activity (Cyr and Domann
2011). Taken together, these data support the concept
that age-related epigenetic pathways can be reversed
leading to a rejuvenated phenotype in HSCs.
The regenerative capacity of HSC transplantation
(HSCT) provides an alternative approach for the
treatment of age-related hematological malignancies.
In HSCT, cells are collected from mobilized blood, bone
marrow or umbilical cord blood and intravenously
injected in the preconditioned recipient (Gupta et al.
2011). The well-established limitation of HSCTs is the
insufficient number of stem cell donors. Moreover, the
potential donor list is further narrowed only to the young
population, because HSCs isolated from older donors
engraft much less efficiently in the recipient bone
marrow than younger HSCs that results in poorer
marrow function (Anasetti 2008). We, therefore, predict
that methods that enhance HSC engraftment in the new
bone marrow microenvironment and procedures that
contribute to the HSC expansion will improve the
efficiency of HSC transplantation in the elderly.
Neural stem cells
In 1962, Altman showed for the first time that the adult
mammalian brain can generate new neurons (Altman
1962). Since then, many researchers have addressed
this topic and today we can unequivocally state that
neurogenesis in mammals continues throughout life.
The importance and impact of the newly generated cells
on the adult CNS function have not been clearly
established, however, rodent experiments indicate that
the adult-born neurons may play a role in the regulation
of olfaction, mood, learning and memory (Gould et al.
1999; Garthe et al. 2009; Lehmann et al. 2013; Lazarini
and Lledo 2011; Goodman et al. 2010; Sahay et al.
2011). However, despite the efforts and interest in the
field, the picture of adult neural stem cells is still
obscure. As mentioned above, stem cells in general are
defined by their ability to self-renew and give rise to
differentiated progenies. The neural stem cells (NSCs)
in the adult brain have not yet been proven to be bona
fide stem cells, since there is an apparent heterogeneity
in the cell populations at multiple stages of adult
neurogenesis (Lugert et al. 2010; Cho et al. 2008;
Conboy and Rando 2005; Decarolis et al. 2013).
The two main regions in the adult brain that give
rise to new neurons are the subventricular zone (SVZ)
lining the lateral ventricles and the subgranular layer
(SGL) of the hippocampal dentate gyrus (Fuentealba
et al. 2012). The cells formed in the SVZ assemble into
a chain called rostral migratory stream (RMS) that,
upon reaching the olfactory bulb (OB), gets anatom-
ically and functionally incorporated into the OB
network (Belluzzi et al. 2003). The neuronal precur-
sors of the SGL, however, differentiate locally and
form connections within the hippocampal circuitry
(van Praag et al. 2002).
The localization, morphology and behavior of the
NSCs greatly differ between the SVZ and SGL.
Nevertheless, similarities between these two popula-
tions during the process of the generation of new
neurons can be observed [reviewed in (Ming and Song
2011)]. In both regions, the NSCs possess radial glia-
like properties, being GFAP- and Nestin-immunore-
active. These cells are in a quiescent state and upon
activation they proceed to a transit-amplifying/pro-
genitor phase in which they rapidly proliferate.
Subsequently, these cells give rise to doublecortin
(DCX)-expressing neuroblasts that eventually turn
into mature NeuN-positive neurons. The new neurons
are generated in a special environment called the stem
cell niche, which contains ependymal cells, astrocytes,
microglia (resident macrophages of the CNS) and
blood vessels (Fuentealba et al. 2012).
Biogerontology (2013) 14:573–590 577
123
Age-related changes in NSCs
In this section we summarized recent studies on the
regulation of adult NSC maintenance and differenti-
ation, with particular focus on aging.
NSC pool and proliferation potential
It is now generally accepted that the production rate of
adult-born neurons decreases with age in the mouse
SVZ and SGL (Maslov et al. 2004; Lugert et al. 2010).
Despite the decline in the number of total NSCs, the
percentage of actively mitotic NSCs increases with
age, suggesting that other downstream processes (such
as altered cell survival or differentiation potential)
should account for the reduction of new-born neurons
in old mice (Shook et al. 2012; Stoll et al. 2011b).
Age-related changes in human neurogenesis
The extent and functional relevance of human neuro-
genesis is still under debate. It has been shown that in
humans there is limited postnatal neurogenesis in the
olfactory bulb (Bergmann et al. 2012) and neurogen-
esis in the neocortex is restricted to perinatal age only
(Bhardwaj et al. 2006). Also, neurogenesis in the SVZ
and the formation on migrating chain of neuroblasts
(RMS) can be observed only in infants and are
basically missing in the adult (Sanai et al. 2011).
Earlier studies from Eriksson et al. (1998) showed
that in post-mortem human hippocampus, BrdU
(thymidine analog labeling the DNA in S phase
administered to the individuals before their death) co-
localizes with neuron-specific markers, suggesting the
generation of new neurons even in middle-aged and
aged persons. Later studies confirmed these findings
and completed the picture with the observations that
qualitative and quantitative age-related changes in the
hippocampus are similar in humans and rodents
(Knoth et al. 2010). In vivo MRI studies revealed
age-dependent shrinkage of the human hippocampus
[reviewed in (Ho et al. 2013)]. Whether the change in
the morphology of this brain region corresponds to
decreasing neuron production is not clear yet.
Marmosets (New World primate) display adult
neurogenesis both in the SGL and SVZ, and aging is
associated with the decrease of DCX-positive neuro-
blasts (Bunk et al. 2011; Leuner et al. 2007). However,
the number of neuroblasts was lower in the marmoset
than in age-matched mouse, further supporting the
idea that evolutionary more developed species such as
humans may not possess extensive adult neurogenesis
(Bunk et al. 2011).
Systemic regulators
Very elegant heterochronic parabiosis experiments, in
which old and young mice (parabionts) were con-
nected in different combinations via their circulation,
demonstrated that factors present in the blood can
affect neurogenesis, synaptic plasticity and spatial
learning (Villeda et al. 2011). Young parabionts
showed reduced neurogenesis in the hippocampus,
while impaired neurogenesis in old mice was partially
rescued. The chemokine CCL11 was identified as one
of the mediators of this process in old mice. Other
chemokines, such as MCP-1 and MIP1, also regulate
the maintenance of adult NSCs cultured in vitro and
contribute to different effects on young and middle-
aged animals (Gordon et al. 2012).
The NSC niche
Several signaling pathways and factors are known to
modulate neurogenesis in the adult and aged CNS
[reviewed in (Artegiani and Calegari 2012; Riddle and
Lichtenwalner 2007)]. Here, we will list only some of
them supported by recent evidence to give a hint on the
several factors at work.
Interestingly, age-related decrease in hippocampal
neurogenesis is not associated with a decline in the
expression of selected genes important for NSC
proliferation and neurogenesis in the dentate gyrus
(DG) (Shetty et al. 2013). However, endothelial cells
in the stem cell niche express more TGF-beta1 in aged
mice than in young adults, which provokes enhanced
quiescence and apoptosis of the NSCs (Pineda et al.
2013). Furthermore, astrocytes located in the niche
secrete VEGF and FGF2 to promote the NSC main-
tenance. During aging, the activity of these cells
decline, which results in decreased growth factor
production and subsequent drop in the level of
neurogenesis (Bernal and Peterson 2011). Astrocytes
are also involved in the regulation of adult NPC
proliferation by mediating Wnt signaling.
In aging, decreased astrocytic activity and cross-
talk lead to reduced Wnt signaling and maintenance of
NSCs (Miranda et al. 2012). Restoring the down-
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regulated levels of Survivin (an Inhibitor of Apoptosis
protein and a downstream target of Wnt), results in
enhanced NPC proliferation in the aging brain. Sox2
also regulates the expression of Survivin and the
apoptosis and the survival of NSCs in the SVZ (Feng
et al. 2013). Reduction of Wnt levels affects the
expression of other target genes, as well, e.g. NeuroD
and DCX that are regulated in a reversible way in an
exercise-dependent manner (Okamoto et al. 2011). In
the hippocampus, the levels of Wnt antagonist Dkk1
increase with age, accounting for the reduced Wnt
signaling. In agreement with these findings, old Dkk1
mutant mice show improved memory consolidation
and affective behaviour (Seib et al. 2013). Besides
astrocytes, microglial cells are also thought to mod-
ulate the Wnt-mediated NSC proliferation via the
secretion of proinflammatory factors in the neurogenic
niche (L’Episcopo et al. 2013). Metabolic changes
(such as decreased mitochondrial content and oxygen
consumption) can also account for altered neural stem
cell behavior and new neuron production in the
nervous system of aged animals (Stoll et al. 2011a).
In sum, the altered microenvironment and signaling
in the NSC niche lead to a reduced rate of neurogenesis
in old age.
NSCs in age-related neurodegeneration
Given the presence and potential functional signif-
icance of adult-born neurons in the CNS, diseases
affecting the nervous system may impinge on or be
modulated by the newly emerging cells from the
neurogenic regions. The most common age-related
neurodegenerative disorders manifested in the brain
are Alzheimer’s disease (AD), Huntington’s disease
(HD) and Parkinson’s disease (PD). The main
features of these pathologies involve aberrant pro-
tein aggregation, selective neuronal loss, and
subsequent physical and mental decline. There are
several genetic rodent models established to inves-
tigate the pathogenesis of the devastating diseases
[e.g. (Elder et al. 2010) for AD; (Cepeda et al.
2010) for HD, and (Magen and Chesselet 2010) for
PD]. Although in most cases these models do not
completely reflect the phenotypes observed in
patients, they serve very valuable subjects to
decipher some basic aspects of the cellular changes
occurring during AD, HD or PD. In the next
section, we summarize the recent progress in the
regulation of adult NSCs in neurodegenerative
disease models.
Alzheimer’s disease
Alzheimer’s disease can be characterized by (i) the
altered processing of the transmembrane amyloid
precursor protein (APP) resulting in the accumulation
of extracellular amyloid-beta deposits (senile pla-
ques), and (ii) the hyperphosphorylation of the
microtubule-associated protein tau that aggregates in
the cell to neurofibrillary tangles. The most affected
brain regions/cell types in AD are the basal forebrain
cholinergic neurons, hippocampus and cortex.
In AD model systems, NSCs of different trans-
genic animals respond differently depending on the
type of transgene [reviewed in (Lazarov and Marr
2010)]. In some models, the NSC proliferation and
differentiation potential increase, whereas in other
models, the opposite effect is observed. In humans,
the picture is also far from being clear: some
research groups showed elevated levels of DCX and
neuron-specific markers (Jin et al. 2004), while
others reported a decrease in DCX-positive cell
number via bone morphogenetic protein 6 (BMP6)
signaling (Crews et al. 2010) in the hippocampus of
AD patients compared to non-demented controls. All
these discrepancies observed both in animal and
human studies may be due to diversity in the utilized
transgenic models, tests performed at different ages
or different stages of the disease. Therefore, further
detailed and systematically comparable studies are
required to draw clear conclusions of the relationship
between AD and neurogenesis. Intriguingly, longi-
tudinal studies in humans and experiments per-
formed in AD transgenic mice have revealed that
enhanced social, mental and physical activity
(enriched environment) in elderly people/aged ani-
mals protects against dementia and AD (Fratiglioni
et al. 2004; Arendash et al. 2004; Jeong et al. 2011).
It would be attractive to speculate that these
protective effects are mediated by NSCs.
Huntington’s disease
Mutations in the huntingtin gene observed in HD
cause the precipitation of the encoded protein product
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that leads to the damage and elimination of medium
spiny GABAergic neurons in the striatum and other
neurons in the cortex.
The HD mouse models suggested that the accumu-
lation of the mutant protein impairs neurogenesis in
the hippocampus (Fedele et al. 2011). Remarkably,
enriched environment (Lazic et al. 2006; Spires et al.
2004; Sullivan et al. 2001), but not physical exercise
(Kohl et al. 2007), could compensate for the reduced
number of neurons. Histological analyses of HD
patients showed increased neurogenesis in the striatum
(Curtis et al. 2003) but not in the hippocampus
[reviewed in (Ransome et al. 2012)], suggesting that
adult-born neuronal progenitors can arise close to the
striatum and migrate to the damaged area to replace
the lost cells. Similarly, when GABAergic neurons
were ablated in the murine striatum, SVZ progenitors
migrated to the lesioned region and gave rise to NeuN-
positive mature neurons (Tattersfield et al. 2004).
These data indicate that upon neuronal cell death,
NSC-derived cells can be attracted to fill the gap in the
neural tissue.
Parkinson’s disease
In PD, the misfolded alpha-synuclein in the dopami-
nergic neurons forms intracellular aggregates that
provoke the selective cell death of the midbrain
dopaminergic neurons. The most prominent clinical
feature of PD is the dysregulation of motor functions
(muscle rigidity, tremor), however, other non-motor
phenotypes appear, as well (e.g. cognitive dysfunc-
tion, depression).
Animal and human studies of Parkinson’s disease
gave more or less clear-cut evidence for impaired
SVZ and SGL neurogenesis [reviewed in (Moc-
hizuki 2011; Marxreiter et al. 2013)]. Although the
exact mechanisms underlying the reduced NSC
proliferative and differentiation potential in PD are
still unknown, recent data suggest that disturbed
Wnt/beta-catenin signaling pathway mediated by
microglial cells could be at work (L’Episcopo et al.
2013).
Interestingly, in patients suffering from all above
listed diseases, olfactory deficit is exhibited even
before the main symptoms (Jimbo et al. 2011; Lazic
et al. 2007; Doty 2012). This raises the possibility of
the involvement of adult NSCs derived from the SVZ
or the SGL in the pathogenesis of the disorders.
Future perspectives
The age-related alterations in NSCs are under exten-
sive debate for several reasons. First, neither marker
nor morphology analyses could identify a single NSC
population in the neurogenic regions of the adult brain.
In addition, the extent of adult neurogenesis seems to
be quite limited, therefore, its relevance in the adult
brain functions is fairly controversial. Finally, it
should be noted that most studies have been carried
out in rodent models while the anatomy and physiol-
ogy of the rodent and human neuronal networks show
some differences. Therefore, the interpretation of the
experimental results needs careful consideration.
Nevertheless, a great body of data has accumulated
over the years about the mechanisms, regulation, and
role of adult neurogenesis and its changes during aging.
This knowledge may be exploited to overcome some
ARDs affecting the nervous system (such as Alzhei-
mer’s, Parkinson’s or Huntington’s disease). One way
to replace the lost cells in the brain is to transplant
neurally committed cells to the damaged area. This
procedure, however, raises serious concerns about the
fate of the injected cells, the extent of regeneration and
its relevance in the above mentioned diseases, since the
pathological phenotype of the diseased endogenous
cells may affect the graft tissue, as well. Another
therapeutic avenue, which seems less invasive, is to
activate the endogenous stem cells located in the
nervous system to replace the eliminated neurons and
glial cells. Nevertheless, the limited availability of
adult NSCs may interfere with this approach to cure
devastating diseases. Further studies in the field will
hopefully shed more light on the process of adult
neurogenesis and will enable the development of
promising and effective strategies to cure at least some
age-related neurodegenerative diseases.
Mesenchymal stem cells
Mesenchymal stem cells (MSCs) were identified
almost forty years ago by the work of Friedenstein
et al. (1976). They described a rare population of cells
that developed into colony forming units following
plastic adherence of bone marrow cells. MSCs are
bone marrow derived, non-hematopoietic cells that
differentiate into cells of the mesenchymal lineage,
including bone, cartilage, adipose, tendon and muscle
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tissue. Additionally, MSCs can give rise to ectoderm-
type cells, e.g. neuron-like cells (Dezawa et al. 2004),
and endoderm-like cells, e.g. hepatocytes (Lee et al.
2004). Notably, one of the challenges in the identifi-
cation of MSCs is the absence of specific surface
markers. The MSCs can be identified by various
markers (such as CD13, CD29, CD31, CD44, CD54,
CD63, CD73, CD 90, CD105, CD106, CD140b,
CD166, Stro1), along with the absence of the hema-
topoietic markers (Colter et al. 2000; Pittenger et al.
1999). The properties of MSCs such as their ease of
culture expansion, immunomodulatory activity, and
differentiation potential make these cells potentially
ideal candidates for tissue engineering and cell
replacement therapies.
Age-related changes in MSCs
Since MSCs may provide a major source of cells for
therapeutic purposes, age-related alterations with
respect to their pool size and function have been
extensively addressed.
MSC pool and proliferation potential
Reports about the effect of aging on isolated human
MSC proliferation are conflicting. In a number of
studies, no significant changes in cultured MSC
doubling time or proliferation capacity have been
observed in young versus elderly people (Scharstuhl
et al. 2007; Suva et al. 2004; Stenderup et al. 2001). In
contrast, several research groups suggested that
increasing age has a negative impact on MSC growth
(Alt et al. 2012; Mareschi et al. 2006; Zaim et al.
2012), cell number and performance (Stolzing et al.
2008). The observed discrepancies might be due to the
fact that different laboratories apply various methods
to derive and culture MSCs (Sethe et al. 2006). As long
as the protocols are not standardized for MSC
isolation, identification, and maintenance, it will be
difficult to draw clear-cut conclusions about the
impact of aging on MSCs’ properties.
MSC differentiation potential
Results surrounding the age-related differentiation
capacity of MSCs, mostly osteogenic differentiation,
are also conflicting (Sethe et al. 2006). Several reports
showed a decrease in osteogenic potential of MSCs
with age. For example, Moerman et al. (2004)
suggested that aging increases the commitment of
MSCs to the adipocyte lineage at the expense of the
osteoblast lineage. However, others reported no
change (Roura et al. 2006; Oreffo et al. 1998).
Interestingly, a study by Murphy et al. (2002) showed
a reduction in chondrogenesis in MSCs from osteoar-
thritis patients, suggesting that the changes in the
differentiation capacity of the cells are the underlying
cause for the increase in bone mass and the loss of
cartilage in osteoarthritis.
The use of MSCs in the therapy of age-related
diseases
MSCs may provide an ideal source for transplantation,
considering that their isolation and application is well
established, and they can be isolated from various
adult tissues.
Diabetes
Diabetes has become one of the major causes of
illness and death in the elderly (Sima et al. 2009). A
large number of studies have reported the application
of MSCs in both type I and type II diabetes. Under
certain conditions, bone marrow derived MSCs from
diabetes patients can differentiate into functional islet
pancreatic cells, suggesting that these MSCs may be
potentially used as a source of autologous insulin-
producing cells for beta-cell replacement (Sun et al.
2007). Also, there is supporting evidence for the use
of allogeneic or xenogeneic MSCs in pancreatic
regeneration as demonstrated by the positive effects
of islet/bone marrow transplantation in a monkey
model (Berman et al. 2010). In addition to regener-
ation mechanisms, the paracrine effects of MSCs
could play an important role in the treatment of
diabetes as demonstrated by in vivo and in vitro
studies (Hu et al. 2009; Xu et al. 2011). The
transplantation of MSCs could enhance regeneration
of endogenous progenitor cells, probably via the
secretion of a variety of factors, such as insulin
growth factor-1 (IGF-1), vascular endothelial growth
factor (VEGF), and basic fibroblast growth factor
(bFGF) (Xu et al. 2011).
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Cardiovascular diseases
The age-related changes in cardiomyocyte structure
and function are a major risk factor for cardiovascular
disease (Sheydina et al. 2011). The acute myocardial
infarction (AMI), which is caused by the obstruction
of the blood supply to the heart with subsequent loss of
cardiomyocytes, is the leading cardiac disease, mostly
occurring in the old population. Early studies offered
therapeutic promise for the application of MSC
engraftment in AMI (Pittenger et al. 1999; Makino
et al. 1999), presumably due to the release of cytokines
and growth factors that stimulate endogenous repair
mechanisms (Amado et al. 2005; Kucia et al. 2004;
Tang et al. 2004). Recent progress from experimental
animal studies and clinical trials supported the bene-
ficial effects of MSCs in AMI treatment. It was further
suggested that the MSCs act by releasing paracrine
signals, by differentiating into cardiomyocytes,
smooth muscle cells, and vascular endothelial cells,
and by stimulating endogenous repair (Boyle et al.
2010).
Neurodegenerative diseases
MSCs can pass the blood–brain barrier, therefore, they
can be delivered to the nervous system without
invasive surgical methods (Momin et al. 2010). The
use of MSCs in the treatment of neurodegenerative
diseases, particularly in fatal and difficult to treat
disorders, such as AD and PD (see previous section), is
under debate. Nonetheless, current data supports that
MSC transplantation is safe and may be used to slow
down the progression of neurodegenerative diseases
(Uccelli et al. 2011; Mezey 2007; Olson et al. 2011;
Spees et al. 2006). For example, previous reports
demonstrated that MSCs survive following transplan-
tation into different mouse models, can differentiate
into neural cells and promote recovery of brain
function (Mezey 2007). They act at least in part by
secreting factors that support injured neurons and
promote the survival and the regeneration of host cells.
Taken together, the existing data support MSC-based
cellular therapies for neurodegenerative disorders
(Mitrecic 2011). However, extensive research and
clinical trials are required to gain further insights into
the underlying mechanisms responsible for the
positive effects of MSC transplantation and to deter-
mine the efficacy of such treatments.
Future perspectives
MSCs possess several key characteristics that make
them potentially ideal cells for cellular therapies
toward aging and ARDs. Depending on their tissue of
origin, MSCs are biased in the type of cells they give
rise to (Porada and Almeida-Porada 2010). Thus
special care needs to be taken in respect to the specific
disease and the target organ. It is reasonable to assume
that variable clinical effects may result from the
diverse methods employed for isolating and culturing
MSCs, differing levels of contaminating cells and the
duration of the culture. Moreover, ARDs are complex,
challenging and not entirely understood, supporting
that their treatment will involve multiple, interdisci-
plinary approaches. Much work remains to be done,
including basic science to further understand the
connection between MSC aging and the major ARDs
as well as clinical trials to explore their potential
clinical use.
Skeletal muscle stem cells
The skeletal muscle satellite cells, or myogenic stem
cells, were first identified and described in 1961 by two
independent studies by Mauro (1961) and Katz (1961).
These cells reside between the myofiber plasmalemma
and the basal lamina. Large body of research con-
ducted since Mauro’s and Katz’s seminal discoveries
showed that these cells are responsible for myofiber
growth and repair [reviewed in (Yablonka-Reuveni
2011)]. The satellite cells were also suggested to play a
role in myofiber hypertrophy during adult life,
although this issue still remains controversial (McCar-
thy and Esser 2007; O’Connor and Pavlath 2007).
Skeletal muscle satellite cells are quiescent under
normal physiological conditions. In response to var-
ious cues, such as exercise, injuries or disease, they
expand, proliferate as myoblasts or undergo myogenic
differentiation to fuse and restore damaged muscle.
Notably, skeletal muscle satellite cells are sustained
throughout adult life due to repeated cycles of growth
and regeneration, underlying their self-renewal prop-
erties and qualifying them as tissue stem cells (Brack
et al. 2007; Collins et al. 2005; Collins and Partridge
2005; Sacco et al. 2008). Recently, a distinct subpop-
ulation of satellite cells has been shown to represent a
reversible dormant stem cell state and generate distinct
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daughter cells by asymmetric DNA segregation during
muscle regeneration (Rocheteau et al. 2012). Over the
years, additional stem cell populations with myogenic
capacity have been identified [reviewed in (Pannerec
et al. 2012)]. Here, we will mainly focus on satellite
stem cells, which are the major skeletal muscle
progenitor cells having indispensable role in myofiber
regeneration.
Age-related changes in skeletal muscle satellite
cells
What happens to skeletal muscle satellite cells with
advanced age? As in most tissues, the regenerative
capacity of satellite cells is reduced. It seems that
satellite cells are different from other tissue stem cells
since they do not lose their ability to participate in
tissue maintenance and repair, but are rather devoid of
the optimal environmental cues required for regener-
ation (Conboy et al. 2005; Conboy and Rando 2005).
Pool of satellite cells
The abundance of resident satellite cells is still under
debate. Whereas some suggested that satellite pool is
relatively constant during aging and may vary,
depending on the specific muscle examined or the
method used (Brack and Rando 2012), others demon-
strated a decline that occurs soon after birth and then
further along with age (Shefer et al. 2013). This
reduction is more striking in females and can be
attenuated by exercise (Day et al. 2010; Shefer et al.
2013; Phelps et al. 2013). Notably, it was recently
suggested that satellite cells comprise two distinct
populations: one, which is responsible for muscle
maintenance throughout life and the number of which
decreases with age, and second, which is activated by
severe muscle injury, survives transplantation and
remains at constant quantities from birth to old age
(Neal et al. 2012).
Regenerative capacity of satellite cells
If indeed the number of clones that produces reserve
cells is reduced with age, then it is possible that
satellite cell depletion is responsible for the reduced
capacity to generate a reserve population (Day et al.
2010). Moreover, additional factors beyond satellite
cell activity play a role in reduced muscle repair in old
age (Shavlakadze et al. 2010). This notion is supported
by the observation that the myogenic stem cell
response is transiently delayed following engraftment
as a result of delayed inflammation, however, the final
regeneration response is proper (Shavlakadze et al.
2010). Indeed, factors in the systemic environment
profoundly regulate the stem cell niche as shown by
the rejuvenation of skeletal stem cells activity using
cross-transplantation (Carlson and Faulkner 1989;
Conboy et al. 2005) or parabiosis (Conboy et al.
2005) of young and old mice. Conversely, a regener-
ative phenotype typical of old age was evident when
young mice were injected with serum obtained from
old mice (Brack et al. 2007). This age-related systemic
effect is associated with an alteration in the myogenic
differentiation potential, expressed as increased fibr-
ogenic lineage potential leading to increased fibrosis
(see below).
Systemic regulators of satellite cells
Given the importance of systemic factors in the control
of muscle regeneration, their signaling pathways have
been extensively studied. A pioneering study by
Conboy et al. (2003), demonstrated that Notch signal-
ing is a key factor of muscle regenerative potential that
declines with age. Notch interplays with the age-
associated excessive production of TGF-beta, which
induces unusually high levels of pSmad3 and hampers
satellite cell regeneration (Carlson et al. 2008). More-
over, Notch is required for the maintenance of the
quiescent state of muscle stem cells by regulating self-
renewal and differentiation (Bjornson et al. 2012).
Satellite cell pool is maintained by Notch since the
deletion of recombining binding protein-Jj (RBP-Jj)
(required for Notch signaling) results in depletion of
stem cells and muscles lacking any ability to regen-
erate in response to injury (Bjornson et al. 2012).
Factors in the systemic environment of old animals
mediate the conversion of satellite cells from myo-
genic to fibrogenic lineage (Brack et al. 2007). These
processes are associated with increased Wnt signaling,
leading to the activation of the downstream effectors
Axin2 and b-catenin. Conversely, inhibition of Wnt
restores muscle regeneration in old mice. It was later
reported that GSK3-beta orchestrates a temporal
switch between Notch to Wnt signaling that regulates
proliferative expansion and subsequently differentia-
tion during postnatal myogenesis (Brack et al. 2008).
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The involvement of Wnt in the regulation of regen-
erative potential of muscle cells was further demon-
strated by the work conducted on the Wnt receptor
Fzd7 and its candidate ligand Wnt7a (Le Grand et al.
2009). Wnt7a promotes the symmetric expansion of
satellite cells without affecting the growth or differ-
entiation of myoblasts and controls satellite cell
number following regeneration. The systemic role of
Wnt in satellite muscle regeneration has been chal-
lenged by showing that Wnt activity was not present in
sera, did not contribute to the TGF-beta1-dependent
inhibition of satellite cell myogenic potential and did
not improve the regeneration of old muscle in vivo
(Carlson et al. 2009).
Satellite cells in muscle disease therapy and future
perspectives
Sarcopenia, the loss of muscle fibers at an advanced age,
is one of the major causes for falls and subsequently
health deterioration in the elderly. The underlying
reason for the reduced muscle mass is not entirely clear,
and the contribution of age-related changes in satellite
stem cell is under debate (Pallafacchina et al. 2012;
Shadrach and Wagers 2011). Most other muscle
diseases including the muscular dystrophies are genetic
disorders associated with progressive muscle weakness
and degeneration. In many of these diseases, myofibers
are readily damaged and their satellite cell mediated
repair leads to the exhaustion of the satellite cell pool.
There is currently no cure for muscular dystrophies;
however, satellite cell (or myotube) transplantation may
provide a promising strategy to slow disease progres-
sion and improve the patient’s quality of life by
enhancing muscle repair [recently reviewed in (Briggs
and Morgan 2013)]. Given that genetic muscle disorders
are not affected by aging classifies them out of the scope
of this review. Nonetheless, understanding the effects of
aging on satellite cells may provide important insights
into transplantation strategies and lead to the identifi-
cation of therapeutic targets.
Satellite stem cells seem to be ‘‘more resistant’’ to
aging than other tissue stem cells (Conboy et al. 2005)
and cells from older animals maintain their regener-
ation properties in a young environment. We therefore
speculate that transplantation of satellite cells will
provide superior results compared to other types of
stem cells with respect to the proportions of functional
transplanted cells. Moreover, the satellite cells are
markedly affected by their niche, supporting that
transplantation of these cells in young patients will
result in better outcomes than in old patients. It would
be interesting to directly check this hypothesis.
Clearly, transplantation success does not only depend
on the functionality of the cells; several challenges,
such as the donor to host histocompatibility or cell
migration, need to be overcome. Moreover, there are
additional complications that are involved in myofiber
regeneration specifically, such as the requirement to
deliver the cells to many host muscles at the same
time. Last but not least, limited understanding of the
niche of satellite cells requires further investigation to
assure that the cells will be provided with the required
environment, including pro-inflammation and stromal
cells (Briggs and Morgan 2013).
Several issues concerning the age-related effects on
satellite cells remain a mystery. The following
questions should be addressed: (1) Will satellite cells
derived from young animals or humans result in
higher therapeutic success? (2) Will the age of the
host influence the functionality and thus the success
rates of the transplantation? Further investigation of
the regulators that are at work during aging will likely
allow increasing the success rates of cell-based
therapies and thus improving the life quality of
muscular disease patients.
Concluding remarks
The association between adult stem cells dysfunction
and aging has been subjected to extensive research.
Here, we emphasize that aging manifests differently in
adult stem cells depending on their tissue of origin
(Table 1). For example, differentiation potential of
HSCs is hampered by differentiation bias as demon-
strated by the accumulation of myeloid-biased cells
(Muller-Sieburg et al. 2012). In the case of satellite
cells, the decreased differentiation potential resulted
from a conversion into a fibrogenic lineage (Brack
et al. 2007). Another important point is the interplay
between the tissue stem cells and their microenviron-
ment. In NSCs, the age-related decrease in hippocam-
pal neurogenesis is associated with altered signals
received from the niche endothelial cells and astro-
cytes (Pineda et al. 2013; Bernal and Peterson 2011).
On the other hand, the dysfunction of blood forming
stem cells with age is thought to be mainly attributed to
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intrinsic regulation (Xing et al. 2006). It is likely that
HSCs are regulated by cues arising from the aged
stroma cells as well, resulting in enhanced mobiliza-
tion and reduced homing of aged HSCs.
Advancing current knowledge in age-related alter-
ations in adult stem cell contributes to our under-
standing of not only the pathophysiological alterations
occurring in ARDs, but also of the use of stem cells in
regeneration medicine. As discussed herein, aging
tissue stem cells are involved in the initiation or
progression of diseases in the elderly, such as in the
cases of HSCs in leukemias, NSCs in neurodegener-
ative diseases and MSCs in osteoarthritis. Further
studies characterizing the involvement of stem cells
and their complex interactions with the microenviron-
ment in the disease are vital. Such studies are expected
to provide new insights into how to modulate the age-
related processes in stem cells and may allow inhib-
iting or delaying the disease progression. Last but not
least, special care needs to be taken when considering
adult stem cells for regenerative therapies since stem
cell function highly depends on the microenviron-
ment, and the aging or imbalanced niche negatively
affects stem cell performance (Larsen et al. 2012).
Thus, a deeper understanding of the in vivo stem cell
regulation will likely contribute to the development of
novel in vitro techniques to model, isolate and
propagate stem cells in a reliable manner to maintain
their capacities for potential use in human therapy.
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